Stevanato Group Q2 Revenue Climbs 8%, Divests Balda C. Brewer, and Lifts Guidance
STVN sits 52% above its 52-week low of $12.89 on elevated volume (2.7× avg).
Summary
Stevanato Group posted Q2 2026 revenue of €302M, an 8% increase, expanded its adjusted EBITDA margin to 26%, and raised full-year guidance. The company also completed the sale of its California-based Balda C. Brewer subsidiary and announced European marketing authorizations for its Alina® pen injector platform.
Key Events · Earnings and Guidance · STVN
-
Q2 Revenue and Margin Beat
Revenue rose 8% to €302.0M, with high-value solutions surging 16% to €135.9M, now 45% of the total. Adjusted EBITDA margin expanded 280 basis points to 26.0%, thanks to operational improvements at the Fishers and Latina plants.
-
Balda C. Brewer Divestiture
The sale of the California-based subsidiary closed on June 30, 2026, resulting in a €12.2M loss. The divested business was on track for roughly €30M in FY2026 revenue; the transaction is expected to be accretive to full-year margins.
-
Raised Full-Year Guidance
FY2026 revenue guidance was narrowed to €1.260B–€1.280B (from €1.260B–€1.290B), adjusted EBITDA was raised to €335.0M–€345.2M, and adjusted diluted EPS was tightened to €0.60–€0.62, reflecting improved currency translation and stronger organic growth.
-
Alina® Pen Platform Commercial Milestone
A customer secured European marketing authorizations for a liraglutide-based therapy using Stevanato's Alina® pen injector and cartridge technology, validating the integrated drug delivery platform in the GLP-1 market.
Analysis · STVN · Industrial Applications And Services
A solid quarter for Stevanato featured 8% revenue growth and a 280-basis-point expansion in adjusted EBITDA margin, fueled by high-value solutions. While the divestiture of Balda C. Brewer triggered a one-time €12.2M loss, it removes a lower-margin business and is expected to be margin-accretive. Management raised the midpoint of adjusted EBITDA guidance and narrowed EPS, underscoring confidence in the core drug containment and delivery operations. The European marketing authorizations for the Alina® pen injector platform represent a major commercial milestone, embedding Stevanato's integrated cartridge and device capabilities in a GLP-1 therapy—a high-growth market.
At the time of this filing, STVN was trading at $19.65 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $12.89 to $28.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.